No profile data available.
Relay Therapeutics, Inc. (RLAY) is a healthcare company in the additional cancer treatment drugs industry, based in Cambridge, United States, with about 202 full-time employees.
It reported revenue of $15.36 million for fiscal year 2025, up 53.4% from fiscal year 2024, and net income of -$276.48 million. Its market capitalization was $3.92 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Relay Therapeutics reported $15.36 million in revenue for fiscal year 2025, up 53.4% from $10.01 million in fiscal year 2024.
$3.92 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include CG Oncology, Inc. (CGON), Erasca, Inc. (ERAS), Cogent Biosciences, Inc. (COGT), Ideaya Biosciences, Inc. (IDYA).